A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating
the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared
to paclitaxel plus placebo.